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Abstract
Purpose To evaluate long-term outcomes in eyes undergo-
ing exchange of fluocinolone acetonide intravitreal implants
for noninfectious uveitis.
Methods In this retrospective case series, chart review was
conducted of all patients treated for noninfectious uveitis
with fluocinolone acetonide implants. All patients were seen
at a single center between 2007 and 2010.We studied eight
eyes of eight patients who received second implants in
exchange for previously placed implants and received
follow-up care after the implant was exchanged. Main out-
come measures were visual acuity (VA), recurrence of in-
flammation, need for adjunctive systemic anti-inflammatory
treatment and adverse events.
Results We studied eight eyes of eight patients. Average
length of follow-up after the second implant was
32.3 months. Of the eight patients, five experienced im-
provement or stabilization of VA when acuity prior to the
initial implant was compared to acuity on long-term follow-
up. After their first implant, five patients experienced dis-
ease recurrence. Including all eight patients, the estimated
median time to recurrence was 35.7 months after the first
implant. The mean time to reimplantation was 42.7 months.
After the second implant, three patients experienced recur-
rence. Including all eight patients, the estimated median
time to recurrence was 30.1 months after the second im-
plant. Adverse events included perioperative complications,
elevated intraocular pressure (IOP) and cataracts.
Conclusions Exchanging FA intravitreal implants used to
treat noninfectious uveitis may be useful in preventing vi-
sion loss and recurrence of inflammation. Development of
elevated IOP and cataract is a potentially serious complica-
tion. The risks and benefits of implant exchange must be
carefully considered with this intervention.
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Introduction
Chronic noninfectious uveitis is a potentially blinding con-
dition [1, 2]. Control of inflammation is imperative to ame-
liorate the individual and socioeconomic impacts of vision
loss from this disorder [3]. Treatment often requires the use
of local and systemic corticosteroids and noncorticosteroid
systemic medications. However, the potential side effects of
systemic medications require regular monitoring [4]. Side
effects are also associated with repeated topical, periocular
and intravitreal corticosteroid treatment [5]. The fluocino-
lone acetonide implant was developed in an attempt to
decrease the risks associated with systemic side effects and
the need for recurrent local corticosteroid treatment. It was
approved by the US Food and Drug Administration for this
use in 2005. The implant is designed to release a controlled
amount of fluocinolone acetonide into the eye for a 30-
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month period. The original study evaluated the safety and
efficacy of the original fluocinolone acetonide implant for
3 years (36 months) after implantation [6]. The corticoste-
roid reservoir is believed to be depleted in 2.5 to 3 years (30
to 36 months); thus far, two follow-up studies have evalu-
ated the safety and efficacy of implant replacement [7, 8].
Average follow-up time in these studies was 17 months. In
this study, we aim to characterize longer-term outcomes in
the eyes of patients with noninfectious uveitis who undergo
exchange of fluocinolone acetonide implants.
Materials and methods
This single-center, retrospective case series was approved
by the institutional review board of Oregon Health & Sci-
ence University. Patients were identified through billing
codes for surgical intravitreal implants placed between
January 2007 and October 2010 at the Casey Eye Institute,
Oregon Health & Science University. Inclusion criteria were
a diagnosis of recurrent noninfectious uveitis, the exchange
of a fluocinolone acetonide implant and at least 1 month of
follow-up after the second implant was placed. Of the
patients who underwent placement of a fluocinolone aceto-
nide implant, eight eyes of eight patients had exchange of
the implant and met the inclusion criteria. Of these eight
patients, two patients went on to receive their third implants.
We reviewed the charts of all eight patients in detail.
The exchange of the intravitreal implants with 0.59-mg
fluocinolone implants was performed in the operating room
by a vitreoretinal surgeon after written informed consent
was obtained. Reimplantation was performed according to
previously described procedures [7, 9]. Each case was left to
the discretion of the operating surgeon as to whether the
original implant was removed and whether the new implant
was placed in the original site or moved to a new site.
Overall, two implants were removed with placement of the
subsequent implant in the same site, and the remainder of
the implants were placed in new sites. All patients were
treated with topical corticosteroids postoperatively and with
oral corticosteroids or other systemic immune system mod-
ulators at the discretion of the surgeon and the uveitis
specialist.
The outcome measures assessed were visual acuity (VA),
recurrence of inflammation, perioperative complications and
adverse events. VA was measured by a Snellen chart before
and after the first, second and, in some cases, third implants.
The best-corrected VA was recorded where available; at
visits where no manifest refraction was performed, the pin-
hole acuity was recorded. Recurrence of inflammation was
defined as one of the following: 1) increase of greater than
or equal to two steps in the number of cells in the anterior
chamber compared to baseline, 2) increase of greater than or
equal to two steps in vitreous haze compared to baseline, 3)
decrease of ≥0.30 logMAR VA compared to baseline with
evidence of either cystoid macular edema (CME) or active
inflammation or 4) development of CME due to inflammation
[6]. In conjunction with recurrence of inflammation, we
assessed the need for systemic corticosteroid or corticosteroid-
sparing medications before the first implant and after the first
and subsequent implants. We also assessed adverse events
including perioperative complications, device-specific compli-
cations, the development of elevated IOP and the formation of
visually significant cataracts. Perioperative complications were
defined as occurring within 90 days of surgery and specific to
the surgical procedure.
Patient demographics were assessed and included gender,
diagnosis, age at first implant, time to second implant, time
to third implant and total days of follow-up. We compared
VA preimplant, postfirst implant and postsecond implant
using the paired t test. Following placement of the first
implants, data were collected at time points ranging from
24 to 36 months postimplant. Following placement of the
second implants, data were also collected at a wide range of
time points, from 16.7 to 43.1 months postsecond implant.
Kaplan–Meier estimates were performed to determine the
time to recurrence after the first, second and third implants.
The development of elevated IOP and cataracts was calcu-
lated using the incidence density.
Results
Eight eyes of eight patients were studied, with demographic
data summarized in Table 1. The average age at first implant
was 40.6 years and 44 years at second implant. The average
time to second implant was 42.7 months. Implant exchange
was recommended based on recurrence of inflammation that
subsided with local or systemic corticosteroid treatment or
on the desire to continue suppressing inflammation when
the implant was theoretically depleted based on prior data
(6). The average time from second to third implant was
30.2 months for the two patients receiving a third implant.
The average length of follow-up after the second implant
was 32.3 months (range 16.7–43.1 months) and 19.5 months
after the third implant (range 5.8–33.2 months).
Final VA comparisons are presented in Table 2. Four of
the eight patients experienced improved VA based on pre-
operative and final follow-up acuity measurements. One
patient maintained stable acuity. Three patients had wors-
ened VA at the final follow-up compared to initial acuity. Of
these, one patient had intractable hypotony maculopathy
5.6 months after the second implant, one patient developed
a subfoveal choroidal neovascularization after the first im-
plant and one patient had recurrent ocular inflammation
despite adjunctive treatment. VA comparisons before and
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after the first implant, before the first and after the second
implants, and after the first and after the second implants
were similar, with a 95% confidence interval (−0.1520,
0.3683), (−0.2626, 0.1992), (−0.3177, 0.1338).
During the 52 weeks prior to receiving the initial fluoci-
nolone implant, all patients had at least one recurrence of
inflammation. After the first implantation, five of the eight
patients experienced a recurrence; however, in one of these
five, the recurrence occurred 1 month after the first implant
was removed due to extrusion of the implant, with implant
removal 49.2 months after placement. After the second
implant, three patients had recurrence of inflammation.
When comparing the first and second implants, the median
time to first inflammation recurrence was 35.7 months for
the first implant and 30.1 months for the second implant.
The Kaplan–Meier curves for these data are in Figs. 1 and 2.
Of the two patients who received a third implant, the first
patient received it secondary to recurrence of inflammation
and the second received it secondary to a desire to prevent
recurrence of inflammation when the implant depleted.
Six of the eight patients were receiving systemic immuno-
suppressive therapy before the first implant. One patient’s
prior immunosuppression status was not known. One patient
never required immunosuppression throughout the disease
process. After the first implant, three of the six patients taking
systemic medication were able to completely taper off immu-
nosuppressive therapy and did not require it again through the
final follow-up visit. One patient remained on systemic im-
munosuppression; however, it was used for joint pain and
never indicated for ocular inflammation. The remaining two
patients required two different systemic immunosuppressive
medications prior to the first implant and only one systemic
medication after both the first and second implants.
Adverse events included perioperative complications,
device-related long-term complications, development of el-
evated IOP and formation of visually significant cataracts.
Perioperative complications occurred after both the first and
second implants. After the first implant, one patient had
perioperative vitreous hemorrhage. Following the second
implant, one patient had an exposed scleral wound requiring
a scleral patch graft and another patient had a vitreous
hemorrhage. Intraoperatively, one patient had a suprachor-
oidal hemorrhage and recurrent retinal detachments during
placement of the third implant, and one patient had con-
junctival dehiscence at the wound site. The only long-term
device-related complication was extrusion of the first im-
plant in one patient 49.2 months after placement. The
implant was removed, and the patient experienced recur-
rent inflammation the following month. A second implant
was placed. A total of six patients developed elevated IOP
after implantation, necessitating four glaucoma surgeries
and two laser procedures in three eyes after the first
implant and three surgeries in three eyes following the
second implant. No surgeries were required following the
third implant. After the first implant, four of four phakic
eyes developed visually significant cataracts requiring
surgery.
Discussion
Chronic noninfectious uveitis is a potentially blinding dis-
ease, with or without treatment. This retrospective case
series demonstrates that exchanging fluocinolone acetonide
intravitreal implants may help prevent vision loss and recur-
rent inflammation.
Table 1 Demographic informa-
tion for eight patients receiving
exchange of fluocinolone aceto-













1 F 25 Multifocal choroiditis No Yes
2 F 45 Sarcoidosis Yes Yes
3 F 41 Multifocal choroiditis Yes Yes
4 M 41 HLA-B27 positive uveitis Yes No
5 M 39 Serpiginous choroiditis No Yes
6 F 63 Birdshot choroidopathy No Yes
7 F 35 Idiopathic panuveitis No Yes
8 M 36 HLA-B27 positive uveitis Yes No
Table 2 Visual acuities of seven
patients receiving exchange of
fluocinolone acetonide implants








Preimplant versus postfirst implant 7 0.1081 0.2813 (0.1813, 0.6194)
Preimplant versus postsecond implant 7 −0.0317 0.2497 (0.1609, 0.5497)
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VA was improved or maintained in five of the eight
patients studied (62.5%) and decreased in three patients
(37.5%) over the course of the treatment. In the three
patients whose VA worsened, one had previously worsened
acuity secondary to hypotony maculopathy from an over-
filtering glaucoma valve. The remaining two patients had
worsened acuity secondary to subfoveal choroidal neovas-
cularization and recurrent inflammation, respectively. These
problems were more likely related to the underlying disease
process and not the implant itself. In all three cases, vision
loss worsened despite adjunctive local or systemic immu-
nosuppression or both. Overall, the comparison of VA prior
to implantation and at final follow-up was not statistically
significant in this small patient population.
In the two prior studies of implant exchange, VA stabi-
lized or improved in 100% of patients [7, 8]. However, both
studies had an average follow-up time of 17 months after the
second implant. Our study had an average follow-up time of
32 months after the second implant. The median implant
survival time prior to recurrence was similar between the
first and second implants, at 35.7 and 30.1 months, respec-
tively. This is similar to the data from the two prior studies
of replacement implants [7, 8]. After the third implant,
median survival time until recurrence was only 8 months;
however, just two patients received a third implant. Of these,
only one patient experienced recurrent inflammation. This
patient had severe recurrent inflammation with all three
implants and was never able to discontinue systemic corti-
costeroid therapy despite adjunctive local and systemic
treatment in addition to the implants. Longer follow-up
may reveal more VA loss, given the chronic nature of
noninfectious uveitis.
Past data suggest that the implant itself may have a poorly
understood mechanism for extended therapeutic effect. Thus,
it is unknown if exchanging a theoretically depleted implant in
a quiescent eye is helpful or if the inflammation would have
remained quiescent despite the intervention. In all six patients
who required systemic immunosuppressive medications
Fig. 1 Kaplan–Meier analysis
of time to recurrence following
implantation of a fluocinolone
acetonide implant in eight
patients treated for
noninfectious uveitis
Fig. 2 Kaplan–Meier analysis
of time to recurrence of




180 J Ophthal Inflamm Infect (2012) 2:177–182
before the first implant, all were able to eliminate or reduce the
number of medications needed to control the inflammation.
This is similar to the findings of the two prior studies of
implant replacement [7, 8].
Adverse effects included perioperative complications,
long-term device related complications and the development
of cataracts and elevated IOP. In most cases, the perioper-
ative complications were easily treated, except in the patient
with suprachoroidal hemorrhage and subsequent recurrent
retinal detachments. This is consistent with prior data re-
garding the implants. The single long-term device-related
complication, implant extrusion, occurred 4 years after the
initial implant and responded well to implant exchange with
no permanent deleterious effects. The risk of perioperative
side effects was similar when comparing the first and second
implants. The development of cataracts occurred during the
first implant and was not a side effect of the second implant,
as the patients had already undergone cataract surgery prior
to the second implant placement. The risk of glaucoma
surgery was similar after the first and second implants (three
patients required surgery after each implant); however, the
number of surgeries required by the three patients was six
after the first implant (including laser surgery), and the
number required by the three patients after the second im-
plant was three surgeries. The development of visually
significant cataracts and elevated IOP is associated not only
with chronic recurrent uveitis but is also a known compli-
cation of the fluocinolone implant [6]. A recent therapy trial
demonstrated favorable outcomes for placement of a glau-
coma tube shunt in conjunction with a first implant in eyes
that already had elevated intraocular pressures (IOPs) on
maximal medical therapy trial [10]. Given the expected high
rates of elevated IOP requiring surgery, clinicians might
want to consider this therapeutic option for future patients.
The current study has several limitations. This is a single-
center retrospective study with a small number of patients.
There is also the possibility of selection bias, in that a group
of patients undergoing multiple intravitreal implants is more
likely to include those patients who responded well to this
approach initially. It might be expected that the complica-
tion rate in patients undergoing a second or third implant
might be less, as this group of patients may have some
physiological reasons for lower complication rates that are
not readily identifiable. Regression to the mean is another
limitation of our study, in that there is a tendency for patients
with multiple recurrences leading up to the intravitreal im-
plant to have fewer recurrences over time. This could be due
to the natural course of the disease and not necessarily to the
implant itself. In addition, this study was not designed to
evaluate and compare findings from each patient’s fellow
eye to determine if the inflammation had naturally run its
course regardless of intravitreal implant placement and ex-
change. Results of the recently published Multicenter
Uveitis Steroid Treatment (MUST) Trial [11] indicated that
VA and inflammation control improved over 24 months in
patients receiving both systemic treatment and intravitreal
implants. There was no clear evidence favoring either ap-
proach. The study concluded that selection of treatment
method should be dictated by the individual patient’s par-
ticular circumstances.
Conclusion
Exchanging a depleted fluocinolone acetonide implant is a
viable treatment for controlling intraocular inflammation
caused by chronic noninfectious uveitis. This treatment
may be helpful in preserving VA and potentially quality of
life, though our study did not directly assess quality of life.
It may also reduce the need for systemic corticosteroids or
corticosteroid-sparing medications, with their associated
side effects. The adverse effects of perioperative complica-
tions, development of cataract and development of elevated
IOP are significant and have been documented in previous
studies. Given the natural history of noninfectious uveitis
and the significant risks of treatment complications from
this therapy, the risks and benefits must be carefully consid-
ered for each patient. MUST Trial results have suggested
that systemic adverse effects of systemic therapy were not
very frequent; thus, the clinician and patient must weigh the
potential risks of subsequent intravitreal implants.
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